Active Ingredient(s): Tivozanib Hydrochloride
FDA Approved: * March 10, 2021
Pharm Company: * AVEO PHARMS
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Fotivda Overview

Tivozanib, sold under the brand name Fotivda, is a medication used for the treatment of relapsed or refractory advanced renal cell carcinoma (RCC).[2] It is an oral VEGF receptor tyrosine kinase inhibitor.[2] The most common side effects include fatigue, hypertension, diarrhea, decreased appetite, nausea, dysphonia, hypothyroidism, cough, and stomatitis.[2] Tivozanib was approved for medical use in the European Union in August 2017,[3&am...

Read more Fotivda Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Fotivda Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Tivozanib Hydrochloride
  • Capsule: 0.89mg, 1.34mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Fotivda: (2 results)

Sorted by National Drug Code
  • 45629-089 Fotivda .89 mg Oral Capsule by Aveo Pharmaceuticals, Inc.
  • 45629-134 Fotivda 1.34 mg Oral Capsule by Aveo Pharmaceuticals, Inc.

Other drugs which contain Tivozanib Hydrochloride or a similar ingredient: (1 result)